CIK 0001604464
- Non-accelerated filer
- Smaller reporting company
Atara Biotherapeutics, Inc.
Sign in to watch- Ticker
- ATRA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 460920988
- Phone
- +1 805-623-4211
- Business address
- 1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA, 91320
- Open-market buys, last 90 days
- $999,994
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$999,994. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −775 | $39.59 | $31K | 271,943 |
| 2019-02-11 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −13,975 | $38.55 | $539K | 272,718 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −2,677 | $38.04 | $102K | 282,903 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −9,698 | $38.78 | $376K | 273,205 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Shares withheld for taxes | −1,512 | $38.47 | $58K | 271,693 |
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Grant or award | +15,000 | 286,693 | ||
| 2019-02-06 | Haqq Christopher EVP, R&D & Chief Scientific Of | Grant or award · Employee Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2018-11-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −775 | $33.81 | $26K | 285,580 |
| 2018-09-26 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −13,500 | $43.08 | $582K | 286,355 |
| 2018-09-25 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −10,000 | $40.26 | $403K | 303,355 |
| 2018-09-25 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −3,500 | $41.23 | $144K | 299,855 |
| 2018-09-24 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −14,069 | $39.74 | $559K | 317,286 |
| 2018-09-24 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −3,931 | $40.53 | $159K | 313,355 |
| 2018-08-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −775 | $37.54 | $29K | 331,355 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise | +25,000 | $11.00 | $275K | 357,905 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −6,885 | $44.44 | $306K | 351,020 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −9,638 | $45.21 | $436K | 341,382 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −9,252 | $46.02 | $426K | 332,130 |
| 2018-05-15 | Haqq Christopher EVP, R&D & Chief Scientific Of | Option exercise · Employee Stock Option (Right to Buy) | −25,000 | 25,000 | ||
| 2018-03-26 | Haqq Christopher EVP, R&D & Chief Scientific Of | Sale | −17,227 | $39.76 | $685K | 334,005 |
Page 1 of 2 · 37 trades